Neuphoria Therapeutics (NASDAQ:NEUP) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Neuphoria Therapeutics (NASDAQ:NEUP) to a hold rating in a research report sent to investors on Saturday.

Several other research firms have also recently weighed in on NEUP. Weiss Ratings reissued a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research report on Monday, June 1st. HC Wainwright cut Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 15th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $21.00.

Neuphoria Therapeutics Stock Performance

NEUP opened at $3.64 on Friday. The stock has a fifty day moving average of $4.29 and a 200-day moving average of $4.39. The company has a market capitalization of $19.66 million, a P/E ratio of -0.33 and a beta of 0.74. Neuphoria Therapeutics has a fifty-two week low of $3.19 and a fifty-two week high of $21.40.

Neuphoria Therapeutics (NASDAQ:NEUP) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.47. On average, equities research analysts predict that Neuphoria Therapeutics will post -4.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in NEUP. Commonwealth Equity Services LLC purchased a new stake in shares of Neuphoria Therapeutics in the 4th quarter worth approximately $43,000. XTX Topco Ltd bought a new stake in Neuphoria Therapeutics in the fourth quarter worth $47,000. Persistent Asset Partners Ltd increased its holdings in shares of Neuphoria Therapeutics by 173.1% during the fourth quarter. Persistent Asset Partners Ltd now owns 13,403 shares of the company’s stock valued at $52,000 after acquiring an additional 8,495 shares in the last quarter. Boothbay Fund Management LLC purchased a new position in shares of Neuphoria Therapeutics in the 4th quarter worth about $54,000. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Neuphoria Therapeutics in the 4th quarter worth about $57,000. Institutional investors own 15.90% of the company’s stock.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.